Bank of Montreal Can Grows Stock Position in Harmony Biosciences Holdings, Inc. $HRMY

Bank of Montreal Can boosted its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 14.6% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,559 shares of the company’s stock after buying an additional 1,729 shares during the quarter. Bank of Montreal Can’s holdings in Harmony Biosciences were worth $428,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Brooklyn Investment Group lifted its holdings in shares of Harmony Biosciences by 1,031.9% in the 1st quarter. Brooklyn Investment Group now owns 1,064 shares of the company’s stock worth $35,000 after acquiring an additional 970 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Harmony Biosciences in the first quarter worth about $57,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Harmony Biosciences by 15.6% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,218 shares of the company’s stock valued at $70,000 after buying an additional 299 shares during the last quarter. CWM LLC grew its stake in shares of Harmony Biosciences by 34.8% during the first quarter. CWM LLC now owns 2,704 shares of the company’s stock valued at $90,000 after buying an additional 698 shares during the last quarter. Finally, IFP Advisors Inc raised its holdings in shares of Harmony Biosciences by 76,666.7% in the first quarter. IFP Advisors Inc now owns 4,606 shares of the company’s stock worth $153,000 after buying an additional 4,600 shares during the period. Institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Price Performance

Shares of NASDAQ HRMY opened at $33.99 on Wednesday. The company has a current ratio of 3.75, a quick ratio of 3.72 and a debt-to-equity ratio of 0.18. Harmony Biosciences Holdings, Inc. has a twelve month low of $25.52 and a twelve month high of $40.93. The stock has a 50 day moving average of $29.63 and a two-hundred day moving average of $32.93. The stock has a market cap of $1.96 billion, a P/E ratio of 10.69, a P/E/G ratio of 0.44 and a beta of 0.85.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.05). Harmony Biosciences had a return on equity of 24.88% and a net margin of 22.50%.The firm had revenue of $239.46 million for the quarter, compared to analysts’ expectations of $222.68 million. On average, research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

HRMY has been the topic of several research analyst reports. Needham & Company LLC cut their price objective on Harmony Biosciences from $48.00 to $41.00 and set a “buy” rating on the stock in a research report on Wednesday, September 24th. UBS Group lowered their price target on shares of Harmony Biosciences from $50.00 to $43.00 and set a “buy” rating on the stock in a report on Wednesday, October 15th. Wall Street Zen downgraded shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. HC Wainwright dropped their target price on Harmony Biosciences from $70.00 to $55.00 and set a “buy” rating on the stock in a report on Thursday, September 25th. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on shares of Harmony Biosciences from $54.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.50.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.